The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation.
The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product to the next clinical stages in humans, with the final goal of reaching in the future a therapeutic market that was estimated in €5,220 Million euro for our main indication (metastatic colorectal cancer), and at the same time exploring its potential use in other IL13Ra2-expressing tumors like melanoma, prostate and lung, among others.
The research consortium is leaded by PROALT and involves strategic partners like the Group of Mechanisms of Cancer Metastasis at the Centro de Investigaciones Biológicas Margarita Salas (CIB) and Medical Applications of Ionizing Radiations Unit at Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).
The ‘Projects in public-private collaboration 2021’ programme is promoted by the State Investigation Agency (AIE) as manager of the State Plan for Scientific and Technical Research and Innovation 2021-2023 from the Ministry of Science and Innovation. The goal of this programme is to promote scientific-technical research and its transfer.